Stock Quote
Idenix Pharmaceuticals, Inc. (IDIX.W) (NASD ADF)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View IDIX on other exchanges
$1.85
10 Nov 2009
-21.28%
$2.35
$1.85
700
$1.86
$1.85
$6.82
$1.86
0.49
296,787
IDIX.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Sommadossi, Jean-Pierre | Chairman of the Board, President, Chief Executive Officer | 2,602,690 |
| Renaud, Ronald | Chief Financial Officer, Treasurer | 802,741 |
| Weidenbruch, John | Executive Vice President, General Counsel, Secretary | 628,348 |
Profile
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company has developed and commercialized a drug for the treatment of hepatitis B virus that it... Full Description
Company Address
Idenix Pharmaceuticals, Inc.
60 Hampshire Street
Cambridge MA 02139
P: +1617.9959800
F: +1617.9959801
60 Hampshire Street
Cambridge MA 02139
P: +1617.9959800
F: +1617.9959801
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Gilead Sciences, Inc. | $46.99 | +0.60 |
| Bristol Myers Squibb Co. | $25.03 | +0.57 |
| IDIX.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.57 |
| P/S(TTM) | 8.82 | 0.57 |
| ROI(TTM) | -73.81 | 1.86 |
| ROE(TTM) | -376.94 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.16 |
| EPS Est. (Current Year) | -0.87 |
| Total Revenue | $3.11M |
| Net Income | $-11.67M |
| EPS | $-0.18 |
